Dell Technologies Inc vs Tempus AI — how do they compare? Dell Technologies Inc trades at $582.07 (market cap $365.31B), while Tempus AI trades at $70.3 (market cap $12.58B). The key difference: Dell Technologies Inc is far larger — about 29× Tempus AI's market cap, and Dell Technologies Inc pays a 0.44% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Tempus AI for 22 Days on average.
| DELL | TEM | |
|---|---|---|
Market Cap | $365.31B | $12.58B |
Volume | 5,121,365 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $588.67 | $99.28 |
52-Week Low | $111.10 | $41.55 |
Typical Hold Time | 57 Days | 22 Days |
Enterprise Value | $388.20B | $13.21B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Dell Technologies trades at $578.96, up 0.9% with strong bullish momentum driven by AI server demand. The stock shows robust technical positioning above key support levels with a bullish moving average signal. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $7.04 surpassing estimates by 43%. The company raised its fiscal 2027 AI server revenue forecast to $74 billion, reflecting strong business momentum and operational discipline.
Dell presents compelling growth prospects with AI server backlog reaching $95 billion and raised revenue guidance. However, investors should monitor execution risks in scaling AI infrastructure and competitive pressures. The stock trades at a premium valuation (P/E 33.68) that requires sustained earnings growth. Analyst consensus remains bullish with 55.6% buy ratings and $566.35 price target.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →